BESPONSA
Google image searchProduct monograph
Active ingredient
inotuzumab ozogamicin, 0.9 MG/VIAL
DIN: 02473909
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE DOSE VIAL
Schedule: Prescription / Schedule D
Company: PFIZER CANADA ULC
Date: 03-MAY-2018
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FB — CD22 (Clusters of Differentiation 22) inhibitors (ATC, ATC/DDD)
- L01FB01 — INOTUZUMAB OZOGAMICIN (ATC/DDD)
Reference brand drug: Besponsa
